← Eichor
Study identifier: NCT07270601 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis

Condition: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease · NAFLD - Non-Alcoholic Fatty Liver Disease  ·  Sponsor: ContextVision AB

PhaseNA
Planned participants110
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersYes

About this study

The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic liver disease (MASLD). Current tests, like MRI or biopsy, can be expensive or invasive. If successful, this ultrasound tool could become an easier and more accessible way to monitor liver health - especially for people with obesity, diabetes, high blood pressure, or high cholesterol.

This description comes directly from the study's public registry record.

Talk to the study team

Laura Sissons-Ross Research Manager  ·  206-616-0397  ·  lsissons@uw.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of WashingtonSeattle, Washington, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07270601